Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.68 USD | +1.49% | +6.99% | -28.58% |
Strengths
- The company shows low valuation levels, with an enterprise value at 0.2 times its sales.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Sector: Managed Healthcare
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-28.58% | 337M | - | ||
-5.91% | 456B | B- | ||
+13.93% | 125B | A- | ||
+18.37% | 101B | B- | ||
-0.28% | 39.69B | B- | ||
-33.18% | 36.86B | A- | ||
-5.28% | 20.05B | B- | ||
-13.82% | 3.08B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- CLOV Stock
- Ratings Clover Health Investments, Corp.